Top Story Today
One FDA Letter, 75% of a Company Gone
Passage Bio is cutting 75% of its workforce after the FDA demanded a randomized controlled trial for its frontotemporal dementia gene therapy, a trial the 24-person company simply cannot afford. The early data looked promising: brain shrinkage slowed 64%, and the target protein was being produced. But regulators wouldn't accept a single-arm study, and Passage Bio's $3.3 million in projected severance costs tells you everything about what comes next. Six employees remain at a company that once aimed to cure dementia with a single injection.
Why it matters: This is the gene therapy sector's economics problem laid bare. When the FDA's (reasonable) evidence standards exceed what small companies can fund, promising science dies on the vine. With Rocket Pharma cutting 30%, the sector is facing a reckoning that pedigree alone can't solve.
Read more →Clinical Wins
Amgen's $1.9B Tepezza Monopoly Just Got Less Comfortable
Viridian's elegrobart hit 63% response versus 18% placebo in active thyroid eye disease, notching another Phase 3 win. The real threat to Amgen: it's a self-administered shot (three doses total) versus Tepezza's eight IV infusions. Chronic TED data drops this quarter, targeting a population Tepezza hasn't cracked.
Read more →Cytokinetics Hands Bristol Myers Its Biggest Headache Yet
New pooled data from 371 patients show Cytokinetics' MYQORZO beat both placebo and metoprolol across every major measure in obstructive HCM. With BMS's Camzyos already failing its non-obstructive expansion trial, Cytokinetics gets its own shot at that larger population in Q2 2026.
Read more →A Breast Cancer Drug That Doesn't Care About Your Tumor's Genetics
Celcuity's gedatolisib just went two-for-two in Phase 3, proving it works in HR+/HER2- breast cancer patients regardless of PIK3CA mutation status. Full data hits ASCO June 2, with an FDA decision on the wild-type indication due July 17. Analysts project $827 million in FY28 revenue, with peak sales estimated at $2.5 billion to $3 billion.
Read more →Funding & Financings
The $700M Startup That's Never Sold a Drug Just Filed to Go Public
Odyssey Therapeutics is back with a $237M IPO target, more than double what it sought before withdrawing last year. The autoimmune-focused platform company has burned $700M in venture capital across multiple pipeline programs in immunology and oncology with zero approved drugs. The 2026 IPO window (already producing $625M raises) might be hot enough to say yes.
Read more →The $97M Bet That Everyone Else Used Too Much Drug
Latus Bio closed a $97M Series A to develop low-dose gene therapy for Huntington's disease, arguing every previous failure shared one flaw: dangerously high viral doses. Their approach screens tens of millions of novel capsid variants to find delivery vehicles so efficient they don't need to flood the brain.
Read more →Industry & Policy
Twenty-One Biotechs Just Formed a New Alliance (and It's Not BIO)
The American Biotech Innovation Alliance launched with 21 founding members, positioning itself as a strategy shop rather than a lobbyist. With FDA instability, pricing threats, and China's biotech rise creating a multi-front war, ABIA wants to build a national "Biotech Vision 2030" before the U.S. loses its edge.
Read more →